Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts rate Design Therapeutics a "Moderate Buy" — seven analysts cover the stock (1 sell, 5 buy, 1 strong buy) with an average 1‑year price target of $16.00.
• Institutions are increasing exposure — Baker Bros., RA Capital and Vivo Capital notably added shares, and institutional investors now own 56.64% of the company.
• Trading/fundamentals snapshot: shares opened at $13.30 with a market cap of $830.7M and a 52‑week range of $3.11–$17.25; last quarter EPS was ($0.29) (beat $0.36 estimate) and analysts forecast full‑year EPS of −1.41.

Shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $16.00.

A number of analysts recently weighed in on DSGN shares. Jefferies Financial Group started coverage on shares of Design Therapeutics in a report on Monday, March 16th. They issued a "buy" rating and a $15.00 price target for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Design Therapeutics in a report on Monday, April 20th. Wall Street Zen lowered shares of Design Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. Piper Sandler reissued an "overweight" rating and issued a $20.00 price target on shares of Design Therapeutics in a report on Wednesday. Finally, Oppenheimer started coverage on shares of Design Therapeutics in a report on Wednesday, January 7th. They issued an "outperform" rating and a $18.00 price target for the company.

Institutional Trading of Design Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Baker BROS. Advisors LP increased its holdings in shares of Design Therapeutics by 30.4% in the fourth quarter. Baker BROS. Advisors LP now owns 2,233,099 shares of the company's stock valued at $20,946,000 after purchasing an additional 520,217 shares in the last quarter. Vivo Capital LLC acquired a new stake in shares of Design Therapeutics in the fourth quarter valued at approximately $15,129,000. RA Capital Management L.P. increased its holdings in shares of Design Therapeutics by 207.2% in the fourth quarter. RA Capital Management L.P. now owns 1,461,381 shares of the company's stock valued at $13,708,000 after purchasing an additional 985,682 shares in the last quarter. Geode Capital Management LLC boosted its stake in Design Therapeutics by 2.4% in the second quarter. Geode Capital Management LLC now owns 794,008 shares of the company's stock valued at $2,676,000 after acquiring an additional 18,511 shares during the last quarter. Finally, State Street Corp boosted its stake in Design Therapeutics by 2.1% in the fourth quarter. State Street Corp now owns 647,636 shares of the company's stock valued at $6,075,000 after acquiring an additional 13,239 shares during the last quarter. Institutional investors and hedge funds own 56.64% of the company's stock.

Design Therapeutics Trading Down 2.2%

NASDAQ DSGN opened at $13.30 on Friday. The firm has a market cap of $830.68 million, a price-to-earnings ratio of -11.08 and a beta of 1.73. The company has a 50 day moving average of $11.40 and a 200-day moving average of $9.70. Design Therapeutics has a 1-year low of $3.11 and a 1-year high of $17.25.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 28th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.07. On average, analysts forecast that Design Therapeutics will post -1.41 earnings per share for the current year.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.